D

Diagnos Laboratorium Utama PT Tbk
IDX:DGNS

Watchlist Manager
Diagnos Laboratorium Utama PT Tbk
IDX:DGNS
Watchlist
Price: 191 IDR 1.06% Market Closed
Market Cap: 238.8B IDR

Profitability Summary

Diagnos Laboratorium Utama PT Tbk's profitability score is hidden . We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Sign Up to see
Profitability Score
Sign In
Sign Up

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

Analyzing past growth in Revenue, Operating Income, and Net Income allows investors to assess the company's profitability and operational efficiency. Consistent improvement in these metrics typically signals long-term strength and stability.

Show More Less

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Show More Less

Earnings Waterfall
Diagnos Laboratorium Utama PT Tbk

Revenue
281.3B IDR
Cost of Revenue
-155.2B IDR
Gross Profit
126.1B IDR
Operating Expenses
-126.2B IDR
Operating Income
-71.6m IDR
Other Expenses
-1.8B IDR
Net Income
-1.9B IDR

Margins Comparison
Diagnos Laboratorium Utama PT Tbk Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
ID
Diagnos Laboratorium Utama PT Tbk
IDX:DGNS
238.8B IDR
45%
0%
-1%
US
CVS Health Corp
NYSE:CVS
99.4B USD
14%
3%
0%
US
Cigna Corp
NYSE:CI
70B USD
10%
4%
2%
US
Cigna Group
XMUN:CGN
60.4B EUR
10%
4%
2%
DE
Fresenius SE & Co KGaA
XETRA:FRE
26.5B EUR
25%
10%
5%
DE
Fresenius Medical Care AG
XMUN:FME
23B EUR
25%
7%
4%
US
Laboratory Corporation of America Holdings
NYSE:LH
21.4B USD
28%
10%
6%
US
Quest Diagnostics Inc
NYSE:DGX
19.9B USD
33%
15%
9%
DE
Fresenius Medical Care AG & Co KGaA
XETRA:FME
11.3B EUR
25%
7%
4%
US
Guardant Health Inc
NASDAQ:GH
12.9B USD
64%
-48%
-44%
US
Hims & Hers Health Inc
NYSE:HIMS
9.1B USD
75%
6%
6%
No Stocks Found

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Show More Less

Return on Capital Comparison
Diagnos Laboratorium Utama PT Tbk Competitors

Country Company Market Cap ROE ROA ROCE ROIC
ID
Diagnos Laboratorium Utama PT Tbk
IDX:DGNS
238.8B IDR
-1%
-1%
0%
0%
US
CVS Health Corp
NYSE:CVS
99.4B USD
1%
0%
7%
1%
US
Cigna Corp
NYSE:CI
70B USD
15%
4%
10%
6%
US
Cigna Group
XMUN:CGN
60.4B EUR
15%
4%
10%
6%
DE
Fresenius SE & Co KGaA
XETRA:FRE
26.5B EUR
6%
3%
7%
4%
DE
Fresenius Medical Care AG
XMUN:FME
23B EUR
5%
2%
5%
4%
US
Laboratory Corporation of America Holdings
NYSE:LH
21.4B USD
10%
5%
9%
6%
US
Quest Diagnostics Inc
NYSE:DGX
19.9B USD
14%
6%
11%
9%
DE
Fresenius Medical Care AG & Co KGaA
XETRA:FME
11.3B EUR
5%
2%
5%
4%
US
Guardant Health Inc
NASDAQ:GH
12.9B USD
192%
-28%
-36%
-67%
US
Hims & Hers Health Inc
NYSE:HIMS
9.1B USD
26%
9%
12%
16%
No Stocks Found

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

Show More Less